Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

American College of Rheumatology Backs Bill to Prevent Cuts to Infusion Reimbursement

Richard Quinn  |  August 21, 2013

The ACR has endorsed a proposed law that would exempt physician-administered drugs from future Medicare sequestration.

The proposed Cancer Patient Protection Act of 2013 (H.R. 1416) would impact Medicare beneficiaries with arthritis and cancer who “depend on drugs administered in their physician’s office to treat their diseases,” ACR President Audrey Uknis, MD, wrote to the bill’s sponsor in a recent letter of support.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“This is a big deal to rheumatologists and their patients who need physician-administered treatments,” adds Adam Cooper, ACR’s director of government affairs.

The bill, introduced in April by Rep. Renee Ellmers (R, NC), remains still mired in committee, but the ACR continues to push for its approval. Tim Laing, MD, chair of the ACR’s Government Affairs Committee, says the issue resonates with rheumatologists who already struggle to make ends meet with in-office treatments.“Office infusions are a small margin part of the practice with very large overhead,” he writes in an e-mail to The Rheumatologist. “You have to buy the drug and get reimbursed. A couple of bad debts can take out the margin for the year. So, sequester cuts a small margin by about a third—so your risk of loss increases.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Prior reimbursement for in-office treatments already often fails to cover actual costs, the ACR says. The current formula for reimbursement for Medicare Part B drugs is average sales price (ASP) plus 6%. The proposed sequestration would reduce the 6% to 4.3%. That could force some providers to stop providing the treatments, while some practices reliant on the revenue stream might even have to shut down.

Dr. Laing says that if rheumatologists stop providing the treatment, it will simply disrupt continuity of care and push patients into less cost-effective settings.

“One way to mitigate the risk is to stop doing infusions and send patients to a hospital,” Dr. Laing writes. But that’s “where charges to insurance are typically higher, which means CMS pays more for the same service.”


Richard Quinn is a freelance writer in New Jersey.

 

Share: 

Filed under:Legislation & Advocacy Tagged with:In-office treatmentMedicareSequestration

Related Articles

    Top 10 Tricks for the Management of Dry Mouth

    February 15, 2023

    PHILADELPHIA—Whether due to Sjögren’s disease or something else, dry mouth is a common chief complaint from patients with rheumatic illnesses. Dry mouth isn’t life-threatening, but it can have a serious impact on quality of life. Sialogogues like cevimeline and pilocarpine may benefit some, but not all, patients, but cholinergic side effects often limit their usefulness….

    What the Affordable Care Act Means for Rheumatology

    January 1, 2014

    Expected to flood the healthcare system with an influx of insured patients, Obamacare will likely exacerbate physician shortages, worsen capacity issues for many rheumatologists, and pressure providers to deliver a measurable quality of care, but analysts say rheumatology patients will benefit from expanded insurance coverage options

    Congress Weighs Medicare Cuts Again

    November 6, 2011

    ACR volunteer leader testified against the cuts, and is optimistic that steep reimbursement declines will be avoided

    Speak Up: Ask Congress to Block Medicare Reimbursement Cuts

    October 22, 2021

    Rheumatologists may need to downsize and restrict patient care if Congress doesn’t act to block significant cuts to Medicare reimbursement rates totaling 9.75% in 2022.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences